Abstract
Hemodynamic disturbance in cerebral blood flow (CBF) is common in both Alzheimer’s disease (AD) and vascular dementia (VaD).The aim of this study is to investigate the different patterns of regional cerebral blood flow (rCBF) change and cerebrovascular reactivity (CVR) in these two types of dementia. Mean flow velocity (MFV) of middle cerebral artery and rCBF were measured by Transcranial Doppler ultrasound (TCD) and arterial spin-labeling (ASL) magnetic resonance, separately. CVR was evaluated by MFV or rCBF change in response to 5% CO2 inhalation. The ASL results showed that, rCBF was significantly lower in both the bilateral frontal and temporal lobes in AD group and lower in left frontal and temporal white matter in patients with VaD. CVR calculated by rCBF was impaired more severely in bilateral frontal cortices in AD. Conversely, TCD tests failed to demonstrate significant difference in MFV and CVR between the two groups. It is concluded that the different patterns detected by ASL in resting rCBF change and cerebrovascular reactivity in response to carbogen inhalation may serve as a potential marker to distinguish AD and VaD.
Keywords: Alzheimer’s disease, Arterial spin-labeling magnetic resonance, Cerebrovascular reactivity, Regional cerebral blood flow, Vascular dementia
Current Neurovascular Research
Title:Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging
Volume: 10 Issue: 1
Author(s): Yong-Zhe Gao, Jun-Jian Zhang, Hui Liu, Guang-Yao Wu, Li Xiong and Min Shu
Affiliation:
Keywords: Alzheimer’s disease, Arterial spin-labeling magnetic resonance, Cerebrovascular reactivity, Regional cerebral blood flow, Vascular dementia
Abstract: Hemodynamic disturbance in cerebral blood flow (CBF) is common in both Alzheimer’s disease (AD) and vascular dementia (VaD).The aim of this study is to investigate the different patterns of regional cerebral blood flow (rCBF) change and cerebrovascular reactivity (CVR) in these two types of dementia. Mean flow velocity (MFV) of middle cerebral artery and rCBF were measured by Transcranial Doppler ultrasound (TCD) and arterial spin-labeling (ASL) magnetic resonance, separately. CVR was evaluated by MFV or rCBF change in response to 5% CO2 inhalation. The ASL results showed that, rCBF was significantly lower in both the bilateral frontal and temporal lobes in AD group and lower in left frontal and temporal white matter in patients with VaD. CVR calculated by rCBF was impaired more severely in bilateral frontal cortices in AD. Conversely, TCD tests failed to demonstrate significant difference in MFV and CVR between the two groups. It is concluded that the different patterns detected by ASL in resting rCBF change and cerebrovascular reactivity in response to carbogen inhalation may serve as a potential marker to distinguish AD and VaD.
Export Options
About this article
Cite this article as:
Gao Yong-Zhe, Zhang Jun-Jian, Liu Hui, Wu Guang-Yao, Xiong Li and Shu Min, Regional Cerebral Blood Flow and Cerebrovascular Reactivity in Alzheimer’s Disease and Vascular Dementia Assessed by Arterial Spinlabeling Magnetic Resonance Imaging, Current Neurovascular Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567202611310010007
DOI https://dx.doi.org/10.2174/1567202611310010007 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognitive Impairment in the Septic Brain
Current Neurovascular Research A Protective Role of Translocator Protein in Alzheimer’s Disease Brain
Current Alzheimer Research Emerging Risk Factors for Cerebrovascular Disease
Current Drug Targets Cannabinoids for the Treatment of Schizophrenia: An Overview
Current Topics in Medicinal Chemistry Therapeutic Angiogenesis in Ischemic Tissues by Growth Factors and Bone Marrow Mononuclear Cells Administration: Biological Foundation and Clinical Prospects
Current Stem Cell Research & Therapy Peptide Sequence Prediction Supported by Correlation-Associated Networks in Human Cerebrospinal Fluid
Combinatorial Chemistry & High Throughput Screening Parkinson’s Disease and Alpha-Synucleinopathies: from Arising Pathways to Therapeutic Challenge
Central Nervous System Agents in Medicinal Chemistry Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors
Current Pharmaceutical Design The Effects of Lipid-Regulating Therapy on Haemostatic Parameters
Current Pharmaceutical Design Regulation of Gene Expression by TDP-43 and FUS/TLS in Frontotemporal Lobar Degeneration
Current Alzheimer Research The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology Molecular Imaging in the Default Mode Network
Current Molecular Imaging (Discontinued) Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
CNS & Neurological Disorders - Drug Targets The CSF p-tau181/Aβ42 Ratio Offers a Good Accuracy “In Vivo” in the Differential Diagnosis of Alzheimer’s Dementia
Current Alzheimer Research Onset Age and Clinical Heterogeneity of Dementias: A Diagnostic and Therapeutic Approach
Current Psychopharmacology Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design